SA Health update: RSV immunisation program
On-demand recorded 27 May 2025
As part of the communication strategy supporting the National Respiratory Syncytial Virus (RSV) Immunisation Program rollout, the SA Health Immunisation Section team and the Chief Public Health Officer, Professor Nicola Spurrier, provide update on program implementation as at 27 May 2025.
Information in this recording:
- Overview of the National Respiratory Syncytial Virus (RSV) Immunisation Program, which commenced in early 2025
- Eligibility of pregnant women for the Abrysvo® vaccine, funded under the National Immunisation Program (NIP)
- The South Australian Government funded program, RSV monoclonal antibody (mAb), Nirsevimab®, for eligible infants whose mothers where not vaccinated in pregnancy, aged up to eight months and eligible infants with specific medical risk factors aged up to 24 months
Learning outcomes
- Interpret the requirements of the National Respiratory Syncytial Virus (RSV) Immunisation Program
-
Distinguish between the vaccine types funded under the program, and who is eligible
-
Identify the specific medical risk factors of infants between 8 and 24 months that make them eligible for the program
Presenter
Prof Nicola Spurrier
Chief Public Health Officer, SA Health